Understanding the impact of Antigen 85 complex substrate specificity on mycobacte
Understanding the impact of Antigen 85 complex substrate specificity on mycobacte
批准号:
7940613
负责人:
Donald R Ronning
金额:
$40.92万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-03-15 至 2013-02-28
关键词:
AG 85Active SitesAddressAffectAffinityAntigensBacteriaBindingBiochemicalBiochemical ReactionBiological AssayCalorimetryCatalysisComplexCord FactorsDataDevelopmentDiseaseEnzymesFutureGenus MycobacteriumGoalsHomologous GeneImmune systemIn VitroInfectionKineticsLeadMeasurementMeasuresMethodsMolecular ConformationMovementMutationMycobacterium tuberculosisOpportunistic InfectionsPharmaceutical PreparationsPlayPreclinical Drug EvaluationReactionResearch Project GrantsRoleSerineShapesSpecificityStructural ProteinStructureSubstrate InteractionSubstrate SpecificityTechniquesTestingThermodynamicsTitrationsTrehaloseTuberculosisVariantX-Ray Crystallographyacyl grouparabinogalactanbasecell envelopedesigndrug developmentin vivoinhibitor/antagonistinterestkillingsmutantmycobacterialnovelnovel therapeuticspathogenic bacteriapreferencepublic health relevanceresearch studytuberculosis treatment
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): To understand the interactions between the Mycobacterium tuberculosis (mtb) antigen 85 enzymes and their substrates, identify components of each enzyme that lead to differences in substrate specificity, identify inhibitors of the catalytic activity, and combine these data to develop novel lead compounds for drug development. The antigen 85 (Ag85) enzymes catalyze the final step required for synthesis of the highly hydrophobic cell envelope of mycobacteria. In vivo studies suggest the three Ag85 enzymes of mtb are responsible for synthesizing different cell envelope components, trehalose dimycolate (TDM) or mycolyl-arabinogalactan (mAG). However, it is not clear how the three Ag85 homologs achieve this substrate specificity and selectivity. In this proposal, we combine biochemical, biophysical, and structural approaches to address this question. This research project is separated into 4 separate but interrelated aspects. First, we will use steady-state kinetics and isothermal titration calorimetry to quantify the enzymatic reaction and binding interactions between the antigen 85 enzymes and their substrates. This will further refine our understanding the different roles these three enzymes play in the bacterium. The second set of experiments uses X-ray crystallography to directly visualize structural changes that occur in the enzymes during catalysis. By obtaining these snapshots of each step in the reaction, we can obtain unprecedented detail about the antigen 85/substrate interactions. The third portion of this study examines the affect of mutations in the enzymes to probe the affects of structural changes on the enzymatic reaction and interactions with the different substrates used by these enzymes. Steady-state kinetics, binding studies, and X-ray crystallography will all be used to examine these mutants. The final method of inquiry will develop novel inhibitors of the antigen 85 enzymes. This will offer two benefits. First, these compounds will be used to study the thermodynamics of complex formation and allow comparison of the three antigen 85 enzymes. Second, these compound represent leads for the development of new therapeutics for the treatment of tuberculosis, lepresy, M. ulcerans infections, and the opportunistic infection by M. avium specied of people with suppressed immune systems.
PUBLIC HEALTH RELEVANCE: Tuberculosis kills more people worldwide than any other treatable disease. Typical treatment with drugs lasts 6 months. Better drugs for treating tuberculosis are desperately needed. Understanding enzyme function in these pathogenic bacteria is central to developing new drugs that specifically inhibit those enzymes and kill the bacteria. This study attempts to better understand the function of 3 tuberculosis enzymes that are important for creating the protective outer layer of the bacteria that cause tuberculosis as a basis for designing new and better drugs to treat tuberculosis.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1586/eri.12.91
发表时间:
2012-09
期刊:
Expert review of anti-infective therapy
影响因子:
5.7
作者:
[Favrot L, Ronning DR]
通讯作者:
Ronning DR
Zafirlukast inhibits complexation of Lsr2 with DNA and growth of Mycobacterium tuberculosis.
Zafirlukast 抑制 Lsr2 与 DNA 的复合以及结核分枝杆菌的生长。
DOI:
10.1128/aac.02407-12
发表时间:
2013
期刊:
Antimicrobial agents and chemotherapy
影响因子:
4.9
作者:
[Pinault,Lucile, Han,Jeong-Sun, Kang,Choong-Min, Franco,Jimmy, Ronning,DonaldR]
通讯作者:
Ronning,DonaldR
Design, synthesis, and X-ray analysis of a glycoconjugate bound to Mycobacterium tuberculosis antigen 85C.
与结核分枝杆菌抗原 85C 结合的糖复合物的设计、合成和 X 射线分析。
DOI:
10.1021/bc3004342
发表时间:
2012-12-19
期刊:
BIOCONJUGATE CHEMISTRY
影响因子:
4.7
作者:
[Ibrahim, Diaa A., Boucau, Julie, Lajiness, Daniel H., Veleti, Sri Kumar, Trabbic, Kevin R., Adams, Samuel S., Ronning, Donald R., Sucheck, Steven J.]
通讯作者:
Sucheck, Steven J.
Evaluating mycothiolation of xenobiotics
-
批准号:10132237
-
项目类别:
-
资助金额:$18.64万
-
财政年份:2020
-
负责人:Donald R Ronning
-
依托单位:
Mycobacterial trehalose metabolism as drug targets
-
批准号:10207440
-
项目类别:
-
资助金额:$42.02万
-
财政年份:2018
-
负责人:Donald R Ronning
-
依托单位:
Mycobacterial trehalose metabolism as drug targets
-
批准号:10114418
-
项目类别:
-
资助金额:$25.95万
-
财政年份:2018
-
负责人:Donald R Ronning
-
依托单位:
Mycobacterial trehalose metabolism as drug targets
-
批准号:10435457
-
项目类别:
-
资助金额:$40.72万
-
财政年份:2018
-
负责人:Donald R Ronning
-
依托单位:
Understanding trehalose synthesis and utilization in mycobacteria
-
批准号:8723058
-
项目类别:
-
资助金额:$36.88万
-
财政年份:2013
-
负责人:Donald R Ronning
-
依托单位:
Understanding trehalose synthesis and utilization in mycobacteria
-
批准号:8883364
-
项目类别:
-
资助金额:$36.88万
-
财政年份:2013
-
负责人:Donald R Ronning
-
依托单位:
Understanding trehalose synthesis and utilization in mycobacteria
-
批准号:8596082
-
项目类别:
-
资助金额:$34.66万
-
财政年份:2013
-
负责人:Donald R Ronning
-
依托单位:
海外基金